

SESSIONS

BIOTECH SHOWCASE 2019 - SUNDAY REGISTRATION - 06/01/2019

Biotech Showcase

January 7-9, 2019

HILTON SAN FRANCISCO UNION SQUARE
San Francisco, CA 94102 USA

Registration Opens - Hilton Union Square

3:00pm - 6:00pm

Hilton Union Square, Plaza A, Lobby Level

All Biotech Showcase attendees are invited to pick up name badges prior to the beginning of the conference on Monday.

SCHEDULE

BIOTECH SHOWCASE 2019 - SUNDAY REGISTRATION - 06/01/2019

Biotech Showcase

January 7-9, 2019

HILTON SAN FRANCISCO UNION SQUARE
San Francisco, CA 94102 USA

TIME	
3:00PM	3:00pm - Registration Opens - Hilton Union Square

SESSIONS

BIOTECH SHOWCASE 2019 - AGENDA - DAY 1 - 07/01/2019

Biotech Showcase

January 7–9, 2019
HILTON SAN FRANCISCO UNION SQUARE
San Francisco, CA 94102 USA

Continental Breakfast - Hilton Union Square

7:00am - 8:00am
Networking

Hilton Union Square, Grand Ballroom

Registration and Tabletop Exhibit Open - Hilton Union Square

7:00am - 6:00pm
Registration

Hilton Union Square, Plaza A, Lobby Level

Investing in next gen immunotherapies: Moving the checkpoint inhibitors to the next level - Hilton Union Square

8:00am - 8:55am
Workshops and Panels 1

Hilton Union Square, Yosemite C

While the frenzy around funding immuno-oncology agents has started to settle down from its peak in 2015–2016, the question remains open as to which if any of these many “first generation” programs for solid tumors looking to enhance the activity of checkpoint inhibitors and/or attempting to render colder tumors hotter will actually provide the next big shift in clinical management. Data to date has been disappointing to mixed at best. When looking to the future of immunotherapy, one wonders if there will be for the foreseeable future only more incremental advances. But where are the next big paradigm shifts going to be, where is the next great target that will supersize foundational checkpoint therapy? This panel will probe these issues especially as they relate to creating value not only for investors and potential partners but most critically for patients.

Participants

Moderator: Jeffrey M. Bockman - Executive VP, Oncology Practice Head, Cello Health BioConsulting

Panelist: Asthika Goonewardene - Senior Biotechnology Analyst, Bloomberg Intelligence

Panelist: Bibhash Mukhopadhyay - Principal, New Enterprise Associates

Panelist: Robert Ross - Chief Medical Officer, Surface Oncology Inc

Panelist: Thomas J. Schuetz - Co-Founder and CEO, Compass Therapeutics

Panelist: Mai-Britt Zocca - CEO, IO Biotech

NASH MOAs: A highly competitive playing field - Hilton Union Square

8:00am - 8:55am
Workshops and Panels 2

Hilton Union Square, Yosemite A

With many new drugs and molecular targets in development and no FDA-approved therapeutics to treat NASH, the competitive environment is heating up. Although there is increased interest in NASH, the complexity as a multi-factorial disease and the long time frame for drug development is not without challenges. What are the key pros and cons of the multiple key mechanisms of action and will there be an approval in 2019?

Participants

Moderator: Yasmeen Rahimi - Managing Director, Senior Research Analyst, Roth

Panelist: Frederic Cren - CEO, Inventiva

Panelist: Carol Gallagher - Partner, NEA

Panelist: Tomas Landh - Innovation Sourcing VP, Senior Principal Scientist, Novo Nordisk

Panelist: Chuck McWherter - CSO, CymaBay

Panelist: Rohan Palekar - CEO, 89Bio

One-to-one meetings - Hilton Union Square

8:00am - 6:00pm
Networking

Hilton Union Square, Grand Ballroom

Introduction and industry update - Parc 55

8:00am - 8:25am
Cell & Gene Therapy State of the Industry Briefing

Parc 55 San Francisco, Cyril Magnin Ballroom

Participants

Speaker: Janet Lambert - CEO, Alliance for Regenerative Medicine

Cell therapy commercialization in oncology - Parc 55

8:25am - 9:05am
Cell & Gene Therapy State of the Industry Briefing

Parc 55 San Francisco, Cyril Magnin Ballroom

Participants

Panelist: Joanna Beck - Executive VP, Global Pharmaceutical Development and Operations, Celgene Corporation

Panelist: Maria Fardis - President and CEO, Iovance Biotherapeutics

Panelist: Steven Kelly - President and CEO, CARISMA Therapeutics

Panelist: Christopher Vann - Chief Operating Officer, Autolus Therapeutics

Company Presentations - Hilton Union Square

8:30am - 12:00pm
Company Presentations

Hilton Union Square,
Yosemite A and C
Franciscan A, B, C and D

The outlook for gene therapy in 2019 - Parc 55

9:05am - 9:50am
Cell & Gene Therapy State of the Industry Briefing

Parc 55 San Francisco, Cyril Magnin Ballroom

Participants

Chair: Matthew Patterson - Chairman and CEO, Audentes Therapeutics; Chairman, Alliance for Regenerative Medicine

Panelist: Dan Faga - Chief Business Officer, Spark Therapeutics

Panelist: Matthew Kane - Co-Founder and CEO, Precision BioSciences

Panelist: Arthur Tzianabos - President and CEO, Homology Medicines

Panelist: Jeffrey Walsh - Chief Financial and Strategy Officer, bluebird bio

SESSIONS

BIOTECH SHOWCASE 2019 - AGENDA - DAY 1 - 07/01/2019

Biotech Showcase

January 7–9, 2019

HILTON SAN FRANCISCO UNION SQUARE
San Francisco, CA 94102 USA

Lunch Plenary: The booming biotech ecosystem: The playing field has evolved, and the bases are loaded. How long will the streak continue? - Hilton Union Square

12:00pm - 1:45pm

Lunch Plenary

Hilton Union Square, Imperial Ballroom

The biotech industry is booming, with growing confidence in the sector, more financing options than ever before, and valuations driving ever higher. In this new, frenetic normal, how can companies prepare for potential turbulence? Success hinges on meaningful engagement with an increasing number of stakeholders, a much earlier and clearer definition of an asset's value and leveraging of new capabilities to shorten the timeline to approval—all while remaining flexible and nimble. This panel will explore the changing global market forces and what it's going to take for biotech to succeed in the face of new demands.

Participants

Moderator: Barbara Ryan - Founder, Barbara Ryan Advisors

Panelist: Michelle Keefe - President, Commercial Solutions, Syneos Health

Panelist: William Newell - CEO, Sutro Biopharma, Inc.

Panelist: Art Pappas - Managing Partner, Pappas Capital

Panelist: James H. Sabry - Global Head, Pharma Partnering, Roche

Panelist: Camille Samuels - Partner, Venrock

Company Presentations - Hilton Union Square

1:45pm - 5:30pm

Company Presentations

Hilton Union Square,
Yosemite A and C
Franciscan A, B, C and D

An H&Q reunion: A retrospective look at the biotech sector with former analysts - Hilton Union Square

4:00pm - 5:00pm

Workshops and Panels 1

Hilton Union Square, Imperial Ballroom

Participants

Moderator: Dennis J. Purcell - Founder and Senior Advisor, Aisling Capital

Panelist: Kristin Carey - Managing Director, Cain Brothers

Panelist: Steve Elms - Managing Partner, Aisling Capital

Panelist: Meg Malloy, Music Therapy

Panelist: Rich van den Broek - Partner, HSMR Advisors

Panelist: Tim Wilson - CEO, IGEM Therapeutics Ltd

Panelist: Alex Zisson - Managing Director, H.I.G. Capital

SCHEDULE

BIOTECH SHOWCASE 2019 - AGENDA - DAY 1 - 07/01/2019

Biotech Showcase

January 7–9, 2019

HILTON SAN FRANCISCO UNION SQUARE
San Francisco, CA 94102 USA

TIME	CELL & GENE THERAPY STATE OF THE INDUSTRY BRIEFING	COMPANY PRESENTA- TIONS	LUNCH PLENARY	NETWORKING	REGISTRATION	WORKSHOPS AND PANELS 1	WORKSHOPS AND PANELS 2
7:00AM				7:00am - Continental Breakfast - Hilton Union Square	7:00am - Registration and Tabletop Exhibit Open - Hilton Union Square		
8:00AM	8:00am - Introduction and industry update - Parc 55 8:25am - Cell therapy commercialization in on- cology - Parc 55	8:30am - Company Pre- sentations - Hilton Union Square		8:00am - One-to-one meetings - Hilton Union Square		8:00am - Investing in next gen immunotherapies: Moving the checkpoint in- hibitors to the next level - Hilton Union Square	8:00am - NASH MOAs: A highly competitive playing field - Hilton Union Square
9:00AM	9:05am - The outlook for gene therapy in 2019 - Parc 55						
10:00AM							
11:00AM							
12:00PM			12:00pm - Lunch Plenary: The booming biotech ecosystem: The playing field has evolved, and the bases are loaded. How long will the streak con- tinue? - Hilton Union Square				
1:00PM		1:45pm - Company Pre- sentations - Hilton Union Square					

SCHEDULE

BIOTECH SHOWCASE 2019 - AGENDA - DAY 1 - 07/01/2019

Biotech Showcase

January 7–9, 2019

HILTON SAN FRANCISCO UNION SQUARE
San Francisco, CA 94102 USA

TIME	CELL & GENE THERAPY STATE OF THE INDUSTRY BRIEFING	COMPANY PRESENTA- TIONS	LUNCH PLENARY	NETWORKING	REGISTRATION	WORKSHOPS AND PANELS 1	WORKSHOPS AND PANELS 2
2:00PM							
3:00PM							
4:00PM						4:00pm - An H&Q reunion: A retrospective look at the biotech sector with former analysts - Hilton Union Square	

SESSIONS

BIOTECH SHOWCASE 2019 - AGENDA - DAY 2 - 08/01/2019

Biotech Showcase

January 7–9, 2019
HILTON SAN FRANCISCO UNION SQUARE
San Francisco, CA 94102 USA

Continental Breakfast - Hilton Union Square

7:00am - 8:00am
Networking

Hilton Union Square, Grand Ballroom

Registration and Tabletop Exhibit Open - Hilton Union Square

7:00am - 6:00pm
Registration

Hilton Union Square, Plaza A, Lobby Level

Cell and gene therapy: The financing surge - Hilton Union Square

8:00am - 8:55am
Workshops and Panels 1

Hilton Union Square, Yosemite A

The pending clinical realization of curative and disruptive therapeutic products has resulted in a poignant shift in the investment and financial landscape. For companies engaged in the development of Gene and Cell Therapies, a ready supply of cash and an up-swell in enthusiasm for the sector has resulted in historical fundraising. We have seen the onset of "mega-rounds" with a \$50–200M Series A. In parallel, there has been a shift in the M&A landscape, where recently companies with little platform validation have been acquired at valuations in the high hundreds of millions. These shifts bring forward some key questions on the future of regenerative medicine/advanced therapies. What are the opportunities and what do investors need to understand to ensure these therapies thrive in the current environment?

Participants

Moderator: Reni Benjamin - Managing Director and Senior Biotechnology Analyst, Raymond James

Panelist: Vered Caplan - CEO, Orgenesis

Panelist: Maha Katabi - Co-Founder and Managing Partner, Oxalis Capital

Panelist: Geoff MacKay - President and CEO, AvroBio Inc.

Panelist: Scott Requadt - Venture Partner, Blackstone

Reexamining Alzheimer's: Is it a singular disease? - Hilton Union Square

8:00am - 8:55am
Workshops and Panels 2

Hilton Union Square, Yosemite C

The medical community is shifting its perspective on Alzheimer's disease from a singular disease to a complex web of Alzheimer's disease-related dementias, and investors need to do the same. By dissecting and appreciating the complexity of the disease, new players with novel approaches to the treatment and management of these conditions are emerging including the need to rethink the targets for drug therapies. Even regulatory agencies are taking a more critical look at the downstream complexities in regard to clinical trials and biomarkers while pushing forward solutions to bolster clinical development. Other organizations must take the same approach and recalibrate their thinking of Alzheimer's as a singular disease. Join us as we discuss what we've learned over the past year and the future of clinical development for Alzheimer's disease.

Participants

Moderator: Kim Goh - Principal, ClearView Healthcare Partners

Panelist: Casey Lynch - CEO, Cortextyme

Panelist: Kenneth I. Moch - President and CEO, Cognition Therapeutics, Inc.

Panelist: Barbara Tate - Venture Partner, Dementia Discovery Fund and SV Life Sciences

Panelist: John Vandermosten - Senior Biotech Analyst, Zacks

One-to-one meetings - Hilton Union Square

8:00am - 6:00pm
Networking

Hilton Union Square, Grand Ballroom

Company Presentations - Hilton Union Square

8:30am - 12:00pm
Company Presentations

Hilton Union Square,
Yosemite A and C
Franciscan A, B, C and D

Lunch Plenary: The financing frenzy: Is it truly the best of times? - Hilton Union Square

12:00pm - 1:45pm
Lunch Plenary

Hilton Union Square, Imperial Ballroom

It has been quite a year for biotech financing with a record number of IPOs (48 by the end of Q3) and a record year for venture investments (\$29.5 billion by October 29, 2018, according to Pitchbook). Companies are going public earlier, there is a significant increase in the size of A rounds creating an increase in access to capital and high valuations. Venture firms are raising new mega funds and are flush with new capital that they need to put to work. Pharma companies in the meantime are questioning the high potential cost of their next M&A and collaboration deals. Will the increasingly solid fundamentals of the biotech sector protect it from the challenges we see the overall market facing? What comes next? Will money continue to flow into this space?

Participants

Moderator: Steve Abrams - Partner, Hogan Lovells US LLP

Panelist: Eric Aguiar - Partner, Aisling Capital

Panelist: Gabriel Cavazos - Managing Director, Leerink Partners LLC

Panelist: Kimberly Ha - CEO and Founder, KKH Advisors

Panelist: Philippe Lopes-Fernandes - Senior VP, Global Head of Business Development and Alliance Management, Merck KGaA, Darmstadt, Germany

Panelist: Marian Nakada - VP, Venture Investments, Johnson & Johnson Innovation - JJDC

Company Presentations - Hilton Union Square

1:45pm - 5:30pm
Company Presentations

Hilton Union Square,
Yosemite A and C
Franciscan A, B, C and D

SESSIONS

BIOTECH SHOWCASE 2019 - AGENDA - DAY 2 - 08/01/2019

Biotech Showcase

January 7–9, 2019

HILTON SAN FRANCISCO UNION SQUARE
San Francisco, CA 94102 USA

To spend or not to spend: Investing for commercial success as an emerging company - Hilton Union Square

4:30pm - 5:30pm
Workshops and Panels 1

Hilton Union Square, Franciscan A

Whether or not the plan is to partner, out-license or go it alone, executives at emerging companies need to understand what levels of spend are appropriate to prepare a product for a successful launch. Many clinical-stage companies find themselves either underfunding and subsequently underperforming in the market, or overfunding and incurring costs that do not add incremental value to commercial success. A strategic analysis of influential factors, such as level of development risk, corporate strategy, customer base characteristics and competitive landscape can help these companies determine whether to spend more or less, earlier or later in the process as they bring their product to market.

Space is limited – Add to your [partneringONE](#) agenda to reserve your spot!

Participants

Facilitator: Naveen Murthy - Managing Director, Syneos Health

The shifting model: How new era, patient-led collaborations are transforming drug discovery and development in rare disease, and beyond - Hilton Union Square

4:30pm - 5:15pm
Workshops and Panels 2

Hilton Union Square, Imperial Ballroom

It used to be that patient groups were involved at the beginning (advocating for research) and the end (demanding access) of drug discovery and development. Today—enabled by the emergence of and access to new technologies and spurred on by the shortcomings of traditional drug discovery and development—rare disease communities are aggregating data, establishing collaborative research networks and nimble partnerships with industry, and even creating companies to accelerate the speed and enhance the productivity of drug discovery. Hear about who and what is behind these models, and implications even beyond rare disease, in particular for investors, from expert stakeholders in a stand-and-deliver format that will keep you energized and engaged.

Participants

Moderator: Walt Kowtoniuk - Principal, Third Rock Ventures

Panelist: Tauhid Ali - VP and Head, Takeda TAK-celerator

Panelist: Daniel Fischer - Founder and CEO, Tevard Biosciences

Panelist: Neil Kumar - CEO and Founder, BridgeBio

Panelist: Christine Waggoner - President and Co-Founder, Cure GM1 Foundation

SCHEDULE

BIOTECH SHOWCASE 2019 - AGENDA - DAY 2 - 08/01/2019

Biotech Showcase

January 7–9, 2019

HILTON SAN FRANCISCO UNION SQUARE
San Francisco, CA 94102 USA

TIME	COMPANY PRESENTATIONS	LUNCH PLENARY	NETWORKING	REGISTRATION	WORKSHOPS AND PANELS 1	WORKSHOPS AND PANELS 2
7:00AM			7:00am - Continental Breakfast - Hilton Union Square	7:00am - Registration and Tabletop Exhibit Open - Hilton Union Square		
8:00AM	8:30am - Company Presentations - Hilton Union Square		8:00am - One-to-one meetings - Hilton Union Square		8:00am - Cell and gene therapy: The financing surge - Hilton Union Square	8:00am - Reexamining Alzheimer's: Is it a singular disease? - Hilton Union Square
9:00AM						
10:00AM						
11:00AM						
12:00PM		12:00pm - Lunch Plenary: The financing frenzy: Is it truly the best of times? - Hilton Union Square				
1:00PM	1:45pm - Company Presentations - Hilton Union Square					
2:00PM						
3:00PM						
4:00PM					4:30pm - To spend or not to spend: Investing for commercial success as an emerging company - Hilton Union Square	4:30pm - The shifting model: How new era, patient-led collaborations are transforming drug discovery and development in rare disease, and beyond - Hilton Union Square

SESSIONS

BIOTECH SHOWCASE 2019 - AGENDA - DAY 3 - 09/01/2019

Biotech Showcase

January 7–9, 2019
HILTON SAN FRANCISCO UNION SQUARE
San Francisco, CA 94102 USA

Continental Breakfast - Hilton Union Square

7:00am - 8:00am
Networking

Hilton Union Square, Grand Ballroom

Registration and Tabletop Exhibit Open - Hilton Union Square

7:00am - 5:00pm
Registration

Hilton Union Square, Plaza A, Lobby Level

The year of RNA and the start of a new era - Hilton Union Square

8:00am - 8:55am
Workshops and Panels 1

Hilton Union Square, Yosemite A

The range of RNA therapeutic modalities has expanded significantly since the first-mover companies such as Alnylam, Ionis and Santaris appeared on the global stage. Today, the industry has propelled a variety of novel approaches into the clinic such as small activating RNAs, microRNAs and has been able to leverage mRNAs to develop uniquely personalized medicine for each individual patient. Many of initial hurdles in delivery or efficacy have also been addressed making it possible to realize the full potential of RNA therapies. What will 2019 bring?

Participants

Moderator: Mani Foroohar - Managing Director, Senior Research Analyst, Leerink Partners

Panelist: Franz-Werner Haas - COO, CureVac

Panelist: Robert Habib - CEO, MiNA Therapeutics

Panelist: Vanessa King - CEO, Virion Biotherapeutics

Panelist: Sean Marett - CBO and CCO, BioNTech

Panelist: Romesh Subramanian - Entrepreneur-in-Residence, Atlas Venture

Rare and orphan diseases: The biotech industry poised to make a dent in treatment and diagnosis - Hilton Union Square

8:00am - 8:55am
Workshops and Panels 2

Hilton Union Square, Yosemite C

There are an estimated 7,000+ rare and orphan diseases, and today there are therapies for about 600 rare diseases. With regulatory benefits of the orphan drug act, new technologies including gene and cell therapy and gene editing, market exclusivity and pricing advantages, many biotech companies and big pharma are focusing on orphan diseases. But some counter that premium pricing will break the US healthcare system and are limiting access to care. What is the cost of life extension or even potentially a cure for a debilitating, life-threatening disease?

Participants

Moderator: Edward Tenthoff - Senior Research Analyst, Piper Jaffray & Co.

Panelist: Jim Healy - General Partner, Sofinnova Ventures

Panelist: Philip Katz - Partner, Hogan Lovells

Panelist: Denise Scots-Knight - CEO and Founder, Mereo Biopharma Group plc

Panelist: David P. Snow - CBO, Eloxx Pharmaceuticals

One-to-one meetings - Hilton Union Square

8:00am - 5:00pm
Networking

Hilton Union Square, Grand Ballroom

Company Presentations - Hilton Union Square

8:30am - 12:00pm
Company Presentations

Hilton Union Square,
Yosemite A and C
Franciscan A, B, C and D

Lunch Plenary: The intersection of policy and sentiment: The impact on the industry and the outlook for the future - Hilton Union Square

12:00pm - 1:45pm
Lunch Plenary

Hilton Union Square, Imperial Ballroom

The biotechnology and healthcare sector is being buffeted by a multitude of forces, including public sentiment around issues like drug pricing. Policymakers are as active as ever, addressing issues like the opioid epidemic, emerging technologies, the rapid integration of digital technologies with medicine, and the overall cost of healthcare. Add to the mix a public and private market whose enthusiasm for this sector has been at an all-time high for a sustained period of time. This panel will discuss the key public policy issues affecting the industry and address the question of how this sector will evolve.

Participants

Moderator: Wade Ackerman - Partner, Covington & Burling LLP

Panelist: Rachel King - CEO, GlycoMimetics, Inc.

Panelist: Jonathan S. Leff - Partner and Chairman, Deerfield Management and Deerfield Institute

Panelist: Joe Panetta - President and CEO, Biocom

Panelist: Lauren Silvis - Chief of Staff to FDA Commissioner Scott Gottlieb, FDA

Panelist: Rick R. Suarez - VP, US Market Access, AstraZeneca

Company Presentations - Hilton Union Square

1:45pm - 5:00pm
Company Presentations

Hilton Union Square,
Yosemite A and C
Franciscan A, B, C and D

Early seed alternative financing - Hilton Union Square

2:00pm - 2:55pm
Workshops and Panels 1

Hilton Union Square, Franciscan A

Participants

Moderator: Ben Johnson - Managing Director, Head, National Early Stage Life Science, SVB Silicon Valley Bank

Panelist: Grace E. Colón - President and CEO, InCarda Therapeutics Inc

Panelist: Natalie Dakers - President and CEO, Accel-Rx

Panelist: Hakan Goker - Senior Investment Director, M-Ventures

Panelist: Lesley Stolz - Head, JLABS CA, Johnson and Johnson Innovation, JLABS

SESSIONS

BIOTECH SHOWCASE 2019 - AGENDA - DAY 3 - 09/01/2019

Biotech Showcase

January 7-9, 2019

HILTON SAN FRANCISCO UNION SQUARE
San Francisco, CA 94102 USA

The Readout Live: A conversation with STAT's biotech team - Hilton Union Square

4:30pm - 5:15pm
Workshops and Panels 1

Hilton Union Square, Imperial Ballroom

After days of trekking in and around Union Square, join STAT's biotech team for a no-holds-barred conversation about the week that was and the year to come. Reporters Adam Feuerstein, Damian Garde, and Rebecca Robbins will break down the most important news stories that you should take away from the week. Then they'll talk about the biggest biotech stories and newsmakers to watch in 2019. Come ready to ask them questions.

Participants

Panelist: Adam Feuerstein - Senior Writer, STAT

Panelist: Damian Garde - National Biotech Reporter, STAT

Panelist: Rebecca Robbins - San Francisco Correspondent, STAT

Closing reception - Hilton Union Square

5:15pm - 6:15pm

Hilton Union Square, Grand Ballroom

SCHEDULE

BIOTECH SHOWCASE 2019 - AGENDA - DAY 3 - 09/01/2019

Biotech Showcase

January 7–9, 2019
HILTON SAN FRANCISCO UNION SQUARE
San Francisco, CA 94102 USA

TIME	COMPANY PRESENTATIONS	LUNCH PLENARY	NETWORKING	REGISTRATION	WORKSHOPS AND PANELS 1	WORKSHOPS AND PANELS 2
7:00AM			7:00am - Continental Breakfast - Hilton Union Square	7:00am - Registration and Tabletop Exhibit Open - Hilton Union Square		
8:00AM	8:30am - Company Presentations - Hilton Union Square		8:00am - One-to-one meetings - Hilton Union Square		8:00am - The year of RNA and the start of a new era - Hilton Union Square	8:00am - Rare and orphan diseases: The biotech industry poised to make a dent in treatment and diagnosis - Hilton Union Square
9:00AM						
10:00AM						
11:00AM						
12:00PM		12:00pm - Lunch Plenary: The intersection of policy and sentiment: The impact on the industry and the outlook for the future - Hilton Union Square				
1:00PM	1:45pm - Company Presentations - Hilton Union Square					
2:00PM					2:00pm - Early seed alternative financing - Hilton Union Square	
3:00PM						
4:00PM					4:30pm - The Readout Live: A conversation with STAT's biotech team - Hilton Union Square	

SCHEDULE

BIOTECH SHOWCASE 2019 - AGENDA - DAY 3 - 09/01/2019

Biotech Showcase

January 7-9, 2019

HILTON SAN FRANCISCO UNION SQUARE
San Francisco, CA 94102 USA

TIME	COMPANY PRESENTATIONS	LUNCH PLENARY	NETWORKING	REGISTRATION	WORKSHOPS AND PANELS 1	WORKSHOPS AND PANELS 2
5:00PM	5:15pm - Closing reception - Hilton Union Square	5:15pm - Closing reception - Hilton Union Square	5:15pm - Closing reception - Hilton Union Square	5:15pm - Closing reception - Hilton Union Square	5:15pm - Closing reception - Hilton Union Square	5:15pm - Closing reception - Hilton Union Square